NCT02627274 2022-11-22
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
Phase 1 Completed
Hoffmann-La Roche
Dana-Farber Cancer Institute